Poster Abstract Session:
233. Clostridium difficile: Therapeutics
Saturday, October 29, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:


Tracks: Epidemiology and Infection Control, Adult ID

Vancomycin as Prophylaxis of Relapsing Clostridium difficile Infection
Valida Bajrovic, M.D. ; Matthew Sims, MD, PhD, FIDSA
Variation in and predictors of vancomycin treatment among patients with Clostridium difficile Infection
Vanessa W. Stevens, PhD ; Karim Khader, PhD ; Richard E. Nelson, PhD ; Damon Toth, PhD ; Molly Leecaster, PhD ; Matthew Samore, MD, FSHEA ; Michael Rubin, MD, PhD, FIDSA
FMT Outcomes in Immunocompetent and Immunocompromised Patients: A Single Center Experience
Kristen Zeitler, PharmD ; Ripal Joshi, PharmD ; Jose Montero, M.D. ; Sally Alrabaa, MD
  • ID Week Poster TGH V2.pdf (370.8 kB)
  • A Retrospective Study of Recurrence Rates of Clostridium difficile Infection After the Use of Fidaxomicin in a Single Institution
    Robert Chow, MD ; Melinda Monteforte, PharmD ; Eric Spitzer, M.D., Ph.D. ; Lorenzo F. Ottaviano, MD ; Amanda Phoenix, PharmD ; Crystal Antoine, MD ; Aisha Khan, D.O, MPH ; Luis a. Marcos, MD, MPH
  • C diff Poster.pdf (130.6 kB)
  • Adherence to Treatment Guidelines for Incident Clostridium difficile Infection in Critically Ill Adults
    Kelly Cawcutt, MD ; Alberto Marquez, RRT ; Rodrigo Cartin-Ceba, MD ; Larry M. Baddour, MD, FIDSA ; Sahil Khanna, MBBS, MS
    Efficacy of Bezlotoxumab in Patients Infected with Strains of Clostridium difficile Associated with Poor Outcomes
    Stuart Johnson, MD, FIDSA ; Susan Sambol, MT ; Emma Best, PhD ; Mark Wilcox, MD ; Dale Gerding, MD, FIDSA ; Karen Eves, BS ; Alison Pedley, PhD ; Nicholas Kartsonis, MD ; Mary Beth Dorr, PhD
    Efficacy of Bezlotoxumab (bezlo) in Prevention of C. difficile infection Recurrence (rCDI) in Patients Receiving Concomitant Systemic Antibiotics (CAs)
    Kathleen Mullane, DO, FIDSA ; Mark Wilcox, MD ; Yoav Golan, MD MS, FIDSA ; Yoshihiko Murata, MD PhD ; Keri Shoemaker, MS ; Michelle Kelly, MS ; Alison Pedley, PhD ; Mary Beth Dorr, PhD
    Factors Associated With Clostridium Difficile Infection Relapse in Patients after Fecal Microbiota Transplant
    Carlos Hartmann, MD ; Sorcha Allen, MD ; Cheryl Griesbach, RN ; Heidi Kosiorek, MS ; Robert Orenstein, DO, FIDSA ; Roberto Patron, MD
  • Hartmann_3579483_35x72_.pdf (69.4 kB)
  • Adherence to Guidelines for Treatment of Clostridium difficile Infection and Clinical Outcomes at a Tertiary Care University Hospital: A Retrospective Study 
    Geoffrey You, MD ; Julia Shor, MD ; Hadi Razjouyan, MD ; Susan Mcgrath, BS, CIC ; Navaneeth Narayanan, PharmD ; Sita Chokhavatia, MD ; Susan Boruchoff, MD, FIDSA, FSHEA ; Tanaya Bhowmick, MD
  • IDSA 2016 v2pdf.pdf (694.2 kB)
  • Clearance of Vancomycin-Resistant Enterococcus Colonization with Fecal Microbiota Transplantation among Patients with Recurrent Clostridium difficile Infection
    Lindsay Eysenbach, AB ; Jessica R. Allegretti, MD, MPH ; Olga Aroniadis, MD ; Lawrence Brandt, MD ; Danyel Donovan, BS ; Monika Fischer, MD, MSCR ; Ari Grinspan, MD ; Zain Kassam, MD MPH ; Colleen R. Kelly, MD ; Christina Kim, BS ; Casey Morrow, PhD ; Majdi Osman, MD MPH ; Julia Quan, BS ; Martin Rodriguez, MD, FIDSA ; Terry Walker, PhD ; Mark Smith, PhD
    Safety and efficacy of fecal microbiota transplantation for recurrent Clostridium difficile infection from an international public stool bank: Results from a 2,050 patient multi-center cohort
    Majdi Osman, MD MPH ; Kelsey O'brien, MPH ; Zachery Stoltzner, BS ; Kelly Ling, BS ; Emily Koelsch, RN BSN ; Nancy Dubois, MSN MBA ; Adila Khoiri, MD ; Kanchana Amaratunga, MD MPH ; Mark Smith, PhD ; Zain Kassam, MD MPH
    Impact of Pharmacist Intervention on Compliance with a Clostridium difficile Treatment Bundle
    Kelsey Powell, PharmD ; Angela Huang, PharmD, BCPS-AQ ID ; Sara Revolinski, PharmD, BCPS
  • ID week CDI poster FINAL.pdf (2.4 MB)
  • Prospective Laboratory Evaluation of Fecal Microbiota Transplantation Donors: Results from an International Public Stool Bank
    Kelly Ling, BS ; Emily Koelsch, RN BSN ; Nancy Dubois, MSN MBA ; Kelsey O'brien, MPH ; Zachery Stoltzner, BS ; Pratik Panchal, MD, MPH ; Kanchana Amaratunga, MD MPH ; Zain Kassam, MD MPH ; Majdi Osman, MD MPH
    Treatment of Clostridium difficile Infection in 10 U.S. Geographical Locations, 2013-2014
    Shannon Novosad, MD, MPH ; Lisa G. Winston, MD ; Helen Johnston, MPH ; Elizabeth Badolato, AAS ; Carol Lyons, MS, MPH ; Monica Farley, MD, FIDSA ; Andrew Revis, MPH ; Lucy Wilson, MD, ScM ; Rebecca Perlmutter, MPH ; Stacy M. Holzbauer, DVM, MPH ; Tory Whitten, MPH ; Erin C. Phipps, DVM, MPH ; Ghinwa Dumyati, MD, FSHEA ; Zintars G. Beldavs, MS ; Valerie L.S. Ocampo, RN, MIPH ; Marion Kainer, MBBS, MPH, FSHEA ; Corinne M. Davis, MPH, MS ; Jamie Barnes, MPH ; Dale Gerding, MD, FIDSA ; Alice Guh, MD, MPH

    CME Credits: No CME credit is offered for this session.

    ACPE Credits:

    ACPE Number:

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.